Page 1 of 1

VEGF and its relationship to inflammatory mediators.

PostPosted: Fri May 25, 2007 2:08 am
by patoco
Vascular endothelial growth factor and its relationship to
inflammatory mediators.

Angelo LS, Kurzrock R.
Authors' Affiliation: Phase I Program, Division of Cancer Medicine,
The University of Texas M. D. Anderson Cancer Center, Houston, Texas.

Requests for reprints: Razelle Kurzrock, Division of Cancer Medicine,
M. D. Anderson Cancer Center, Unit 422, P.O. Box 301402, Houston, TX
77030. Phone: 713-794-1226; Fax: 713-563-0566; E-mail: and Laura S. Angelo, Division of Cancer
Medicine, M. D. Anderson Cancer Center. Phone: 713-817-2123; E-mail:


Inflammation occurs in response to host injury or infection, as the
result of an autoimmune disease, or in response to the development of
a tumor. Although the immune system may be helpful in fighting the
tumor, it may also fuel the tumorigenic process. In fact, recent data
suggest a strong link between chronic inflammation, angiogenesis, and
the development of cancer. For example, inflammation and scarring
caused by recurring infections with Mycobacterium tuberculosis may be
a cause for cancers of the lung. Inflammatory breast cancer exhibits
increased angiogenesis and lymphangiogenesis and has a higher
metastatic potential than noninflammatory breast cancer. Nonsteroidal
anti-inflammatory drugs have been proposed as preventives for the
development of colon carcinoma and ovarian cancer. Inhibition of
nuclear factor-kappaB contributes to the proposed mechanism of action.
Inflammatory cytokines, including interleukin-6, serve as autocrine
and paracrine growth factors for several cancers, and high levels of
these cytokines may correlate with a poor prognosis and increased
production of angiogenic factors. The state of the art of our
understanding of this critical interaction is reviewed. ... 13/10/2825


Pat O'Connor
Lymphedema People